

April 21, 2022

To,

BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LTD

Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block

Dalal Street Bandra-Kurla Complex, Bandra (East)

Mumbai - 400001 Mumbai - 400051

<u>Sub: SEBI Circular No. SEBJ/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 - Fund</u> <u>raising by issuance of debt securities by Large Entities</u>

Dear Sir/Madam,

With reference to above circular, we would like to inform you that our Company- Sharon Bio-Medicine Limited is a Large Corporate (LC) as per the framework provided in the aforesaid Circular.

ANNEXURE A Format of the Initial Disclosure to be made by an entity identified as a Large Corporate

Sr.	Particulars	Details
No.		
1	Name of the Company	SHARON BIO- MEDICINE LIMITED
2	CIN	L24110MH1989PLC052251
3	Outstanding borrowing of Company as on 31st	891.4
	March, 2022 (in Rs cr)	
4	Highest Credit Rating During the previous FY	-
	along with name of the Credit Rating Agency	
5	Name of Stock Exchange in which the fine shall	BSE
	be paid, in case of shortfall in the required	
	borrowing under the framework #	





Further, we would like to state that Sharon Bio-Medicine Limited, a Company incorporated under the Companies Act, 1956 having its registered office at W-34 34/1 MIDC Taloja Raigad MH - 410208 ("Company") has undergone a corporate insolvency resolution process ("CIRP") under the aegis of the Insolvency and Bankruptcy Code, 2016 ("IBC"). The CIRP commenced on April 11, 2017 and culminated with the approval of a resolution plan by the National Company Law Tribunal ("NCLT"), Mumbai, vide its order dated March 8, 2018 in respect of the Company.

The order passed by NCLT was upheld by National Company Law Appellate Tribunal ("NCLAT") on December 19, 2018 and thereafter by Supreme Court in its hearing dated April 5, 2019.

Currently, the Company is awaiting clarifications from NCLT in reference to the Supreme Court order dated 28th February, 2022 directing re- initiation of CIRP.

For **SHARON BIO- MEDICINE LIMITED**

Sd/-

Kaushik Banerjee

Chief Executive Officer